Short Interest Coverage: Can Biodelivery Sciences International Incorporated (NASDAQ:BDSI)’s Tomorrow Be Different? The Stock Had Decline in Shorts

November 25, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest Coverage: Can Biodelivery Sciences International Incorporated (NASDAQ:BDSI)’s Tomorrow Be Different? The Stock Had Decline in Shorts

The stock of Biodelivery Sciences International Incorporated (NASDAQ:BDSI) registered a decrease of 16.06% in short interest. BDSI’s total short interest was 6.40 million shares in November as published by FINRA. Its down 16.06% from 7.63M shares, reported previously. With 500,000 shares average volume, it will take short sellers 13 days to cover their BDSI’s short positions. The short interest to Biodelivery Sciences International Incorporated’s float is 14.13%. About 378,979 shares traded hands. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has declined 52.83% since April 22, 2016 and is downtrending. It has underperformed by 58.24% the S&P500.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The company has a market cap of $96.65 million. The Firm develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. It currently has negative earnings. The Firm develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insitutional Activity: The institutional sentiment increased to 0.82 in Q2 2016. Its up 0.25, from 0.57 in 2016Q1. The ratio is positive, as 30 funds sold all BioDelivery Sciences International, Inc. shares owned while 30 reduced positions. 13 funds bought stakes while 21 increased positions. They now own 29.37 million shares or 23.18% less from 38.23 million shares in 2016Q1.
Aqr Cap Management Ltd Liability Company reported 12,873 shares or 0% of all its holdings. The New York-based Millennium Management Limited Liability Co has invested 0.01% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Moreover, Blackrock Institutional Na has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 977,251 shares. Next Finance Group Inc last reported 0.03% of its portfolio in the stock. Pnc Financial Gru Incorporated holds 138 shares or 0% of its portfolio. Tfs Cap Limited owns 26,444 shares or 0.01% of their US portfolio. Davenport & Ltd Com has invested 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Price T Rowe Associate Md last reported 31,500 shares in the company. Armistice Cap Ltd Liability has invested 2.38% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Creative Planning holds 2,300 shares or 0% of its portfolio. Buckingham Asset Mgmt last reported 35,600 shares in the company. Condor Mgmt has 0.01% invested in the company for 15,635 shares. Blackrock Fund has 0% invested in the company for 123,009 shares. Oxford Asset Management, a United Kingdom-based fund reported 227,118 shares. Renaissance Tech Ltd Liability Corporation has 1.71 million shares for 0.01% of their US portfolio.

Insider Transactions: Since August 11, 2016, the stock had 2 buys, and 4 sales for $436,107 net activity. ODONNELL FRANCIS E JR had sold 100,000 shares worth $256,500. Feinberg Barry I bought 2,500 shares worth $6,375. 14,800 shares with value of $36,112 were sold by De Paolantonio Ernest Robert on Wednesday, September 21. STONE WILLIAM B sold $41,120 worth of stock. 47,000 shares were sold by Vasisht Niraj, worth $114,360 on Wednesday, September 21.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Out of 5 analysts covering BioDelivery Sciences International (NASDAQ:BDSI), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. BioDelivery Sciences International has been the topic of 9 analyst reports since August 16, 2015 according to StockzIntelligence Inc. On Wednesday, November 4 the stock rating was initiated by Cantor Fitzgerald with “Buy”. The stock has “Hold” rating given by Cantor Fitzgerald on Wednesday, May 11. Roth Capital maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Friday, March 11. Roth Capital has “Buy” rating and $9 price target. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has “Buy” rating given on Sunday, August 16 by William Blair. As per Monday, February 8, the company rating was initiated by Piper Jaffray. FBR Capital maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Tuesday, November 10. FBR Capital has “Mkt Perform” rating and $14 price target. The rating was maintained by Piper Jaffray with “Overweight” on Thursday, May 12. On Friday, September 23 the stock rating was upgraded by Janney Capital to “Buy”. Janney Capital initiated the stock with “Neutral” rating in Tuesday, October 27 report.

BDSI Company Profile

BioDelivery Sciences International, Inc., incorporated on April 18, 2002, is a specialty pharmaceutical company. The Firm develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Firm develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Another recent and important BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news was published by Prnewswire.com which published an article titled: “BioDelivery Sciences to Present at the 28th Annual Piper Jaffray Healthcare …” on November 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>